
This Direxion Daily Biotech Top 5 Bull 2X ETF aims to provide daily investment returns equivalent to 200% of the performance of the NYSE Biotechnology Top 5 Equal Weight Index, before factoring in its fees and expenses. Please note that the fund offers no assurance of consistently meeting its stated investment targets.
Is TBXU's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

In October 2025, Direxion Investments welcomed a new family of ETFs into their ever-growing roster of leveraged and inverse funds: the Titans ETFs. The suite of funds essentially give traders a middle ground when deciding between broad sector exposure and single-stock opportunities.

In October 2025, Direxion Investments welcomed a new family of ETFs into their ever-growing roster of leveraged and inverse funds: the Titans ETFs. The suite of funds essentially give traders a middle ground when deciding between broad sector exposure and single-stock opportunities.

Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.

Direxion expanded its existing product lineup of leveraged and inverse exchange-traded funds (ETFs) with a new suite: the Titans Leveraged & Inverse ETFs. The funds offer a middle-ground approach that eschews the concentration risk inherent in single-stocks ETFs.